# Daniel O' Mahony

> Daniel O' Mahony is a Series A investor at Seroba Life Sciences backing Health Care and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Seroba Life Sciences](https://shizune.co/investors/profile/seroba-life-sciences)
- Location: Dublin, Ireland
- Total investments: 6
- Last investment: Mar 2025
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/daniel-o-mahony-b02a1413

Daniel O' Mahony is a Series A investor at Seroba Life Sciences in Dublin focused on Health Care and Medical. Daniel O’ Mahony has 26 years international experience at a senior level of management in industry and scientific research, ten years of which were at Elan Corporation where he held the positions of VP Technology & Asset Divestment and VP Experimental Biology followed by R&D Director at Taro Pharmaceuticals. He has held academic postsat the Biochemistry Department, University College Cork; the Genetics Department, Trinity College, Dublin; The Weis Research Centre, PA, USA; the Department of Medicine & Experimental Therapeutics, University College Dublin and the Mater Hospital Centre for Cardiovascular Science. He established the very successful Technology Transfer Office at the National University Ireland, Galway in 2005. His skills encompass major aspects of biopharmaceutical and biotechnology industries, technology licensing from university sector and campus company formation. He is a named inventor on 25 patents, author of over 40 publications and presenter and speaker at numerous international conferences. He sits on the board of a number of private companies. He holds a Ph.D in biochemistry and molecular genetics from University College Cork and a business degree in technology management from the Smurfit business school, University College Dublin. He has been a member of Kernel Capital Advisory board since 2002 and since then he has lead over 25 comprehensive due diligence reviews on behalf of the firm. He commenced a full time position with Kernel as a Partner in January 2008.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Medical | 2 | 33% |
| Biotechnology | 2 | 33% |
| Medical Device | 2 | 33% |
| Fitness | 1 | 17% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series B | 2 | 33% |
| Funding Round | 1 | 17% |
| Venture - Series Unknown | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Perfuze | Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway. | $23.9M |  | Mar 13, 2025 |  |
| Perfuze | Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway. | $25.7M | Series A | Feb 07, 2022 |  |
| INNOVO by Atlantic Therapeutics | Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enablingbladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.It was established in Galway, Galway in 2013. |  | Venture - Series Unknown | Mar 08, 2021 |  |
| INNOVO by Atlantic Therapeutics | Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enablingbladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.It was established in Galway, Galway in 2013. | $30.7M | Series B | Jan 07, 2019 |  |
| INNOVO by Atlantic Therapeutics | Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enablingbladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.It was established in Galway, Galway in 2013. | $16.5M | Series A | Mar 01, 2017 |  |
| Novate Medical | NOvate Medical Technologies is a New Orleans-based medical device development company, focused on commercializing high-quality, low-cost, and sustainable medical products while addressing critical global health needs. NOvate’s first product offering, InfaClip, previously known as SafeSnip, is a patented disposable plastic obstetric device thatsimultaneously cuts, clamps, and shields the infant, mother, and birthing attendant from infection, aimed at reducing maternal and neonatal mortality in developing countries. | $9.9M | Series B | May 21, 2011 |  |

6 of 6 investments shown.

## Co-investors
- [Earlybird Venture Capital](https://shizune.co/investors/profile/earlybird-venture-capital) — VC Fund, 3 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 3 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 3 deals together
- [Atlantic Bridge](https://shizune.co/investors/profile/atlantic-bridge) — VC Fund, 2 deals together
- [EarlyBird](https://shizune.co/investors/profile/earlybird-3) — VC Fund, 2 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together

## About Seroba Life Sciences

VC Fund · Dublin, Ireland

Seroba is a life sciences venture capital firm, focused on investing in breakthrough healthcare technologies that promise to improve lives and make a difference worldwide.Headquartered in Ireland, the firm works with some of the world’s best entrepreneurs developing innovative medical devices, diagnostics, and therapeutic drugs. It funds newhealthcare opportunities through key value-adding stages, assisting its invested companies from inception through development and clinical evaluation, the generation of intellectual property, regulatory approvals and market launch, and partnering with leading pharmaceutical or medtech companies.The Seroba team combines in-depth scientific and medical knowledge with broad regulatory and commercial expertise. They are known for patience, understanding, commitment and passion, well-demonstrated by the caliber of entrepreneurs they back, and an overriding focus on delivering improvements to people's lives and value to their stakeholders.

5 contacts available at Seroba Life Sciences.

| Name | Title | Profile |
| --- | --- | --- |
| Alan O'Connell | Partner | https://shizune.co/investors/profile/alan-oconnell |
| Bruno Montanari | Partner | https://shizune.co/investors/profile/bruno-montanari |
| Daniel O' Mahony | Partner | https://shizune.co/investors/profile/daniel-o-mahony |
| Seamus O’Hara | Director | https://shizune.co/investors/profile/seamus-ohara |
| Andrew Duignan | CFO | https://shizune.co/investors/profile/andrew-duignan |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Daniel O' Mahony invest in?

Daniel O' Mahony invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Daniel O' Mahony last invest?

The most recent investment recorded for Daniel O' Mahony closed in Mar 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co